<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 344 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page343.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=344">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 344 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 344</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=344"><img src="../thumb/344.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.7                                                        2020-04 / 307
       Side-effects: Antibodies to growth horm., headache, musc./joint   Indications: Endometrios.in women 18 yrs & over for 6 mnths.,   interv. & 37,5-75 IU increm. Optim.follicul. developm. may req.up to
       pain, weakn., hyperglycaem., glucosur., loc.reacts., oed., allerg. re-  palliative treatm.of advanc. prostat. Ca. when orchiectomy/estro-  225 IU lutropin alfa & 150 FSH/day in some pts. When optim.respons.
       acts., leukaem.in childr., paraesthes., hypertens., joint disords.&   gen admin.not indic./ unaccept.to pt., adjuv.ther.to surg.in breast   obt. admin. sngl.inj.of 5 000-10 000 IU hCG 24-48 hrs. aft. last Luveris &
       carpal tunn.syndr.in adults, intracran. hypertens.  Ca, centr.precoc.puberty in childr. accord.to clinic. diagn.& base-  FSH inj. Coitus recomm.on day of & day follow.hCG admin./IUI perform.
       Special precautions: IC les.must be inact., anti-tumour ther.compl.  line eval.criteria  Consid. luteal phase support as lack of luteotroph. activ. aft. ovulat.may
       bef.start.ther., special.phys.use only, dos.reduct., increas.age , ex-  (S4) DEPOT INJ. 3,75, 27/21.10/0370, 27/34/0371. 3,75 mg  lead to premat.fail.of corpus luteum. Withold hCG and stop treatm. if
       cess. body mass, test for antibod.in fail.to respond to ther., verify di-  806382-007: Sngl.dos.vial & dil, R2 243,90  excess. respons. obt. & recommence treatm.in next cycle at low.FSH dos.
       agn.bef.init.treatm., discont.if tumour growth evid., prev. treat.childr.  Dosage: Admin. 3,75 mg monthly as sngl.IM/SC inj. Vary inj.sites.  Contraindications: Ovar./uter./mammary Ca, act. untreat.hypo-
       to be re-eval.bef.start.ther. with adult dos., outweigh benef.-risk in   Breast Ca: 3,75 mg 4 wkly.as sngl.IM/SC inj.  thalam.& pituit.tumours, ovar. enlargem./ cyst not due to polycyst.
       ac.critic.ill pts., reduc.dos.in pts.with persist.oed.& sev. paraesthes.   Centr.precoc.puberty in childr: Indiv.bas.on mg/ kg. Young.childr.  ovar.dis.& of unknown orig., gynaecolog.bleed.of unknown origin.,
       to avoid carpal tunnel syndr., freq. monit. of pts.with intracran.les.,   req.high.dos. Monit.by GnRH stimulat. test./sex.ster.& Tanner stag.1-  pregn.& lactat., prim.ovar.fail., uter.fibroid tumour imcompatible with
       poss.malign. transformat. of skin les., gluc.intol.esp.in diab. mellit.,   2 mnths aft. init./dos.chang.to confirm down regulat. Monit. bone   pregn., malformat.of sex.org. incompat. with pregn.
       glucocortic.dos. adjustm.in ACTH-defic. pts., monit.stand.hormon.  age advancem.6-12 mnthly. Titrat.dos. upwards. until no progress.of   Side effects: Ovar.hyperstimulat.syndr., thromboembol., adnexal
       replacem.in hypopituitarism, inadeq.hypothyroid.treatm.may pre-  condit by clinic.& lab. paramet.noted. First dos.result.in adeq. down-  torsion, haemoperitoneum, ectop.pregn., loc.reacts., headache,
       vent optim.respons., period.thyroid funct.tests advis., eval.limp in   regulat. poss.maint.for durat.of ther. Consid. childs weight changes.   somnol., naus., abdom./pelvic or breast pain, ovar.cyst., hypersens.
       childr.for poss.slipp.epiphys., fundoscop.exam. recomm.init.& dur.  Consid.discont.bef.age 11 in fem.& age 12 in males. Init dos: 0,3 mg/  reacts., GI disords.
       treatm., monit. S&S intracran. hypertens.  kg for 4 wks. (min.7,5 mg) IM/SC. &lt; 25 kg: 3,75 mg x2 as one inj with   Warnings and special precautions: Incr.ovar. hyperstimulat.
       Drug interactions: Excess.glucocortic.therapy inhibit.growth   tot.dos.of 7,5 mg. 25-37,5 kg: 3,75 mg x3 as two inj with tot.dos.of   syndr.risk, withhold hCG admin.if signs of ovar.hyperstimulat.occur
       promot.eff.                   11,25 mg. &gt; 37,5 kg: 3,75 mg x4 as two inj with tot.dos.of 15 mg.   & avoid sex. intercourse/ use barrier contracept.x4 days, monit. ovar.
                                     When 2 inj. reqd.for tot.dos.admin.them at same time. Maint. dos:   respons.with ultrasound & ser.oestrad.lev., multip. pregn.risk., pos.
       LEUPROLIDE HEXAL, Sandoz &    If down regulat.not achiev.titrat. upwards in 3,75 mg increm.every   ovar.torsion risk, fertil. eval. of both partn.bef.start.treatm., eval.for
       Leuprorelin.                  4 wks. Reconstit. & admin.mnthly.as sngl.IM/SC inj.  hypothyroid./ adrenocortic.defic./ hyperprolactinaem & pituit./hypo-
       Indications: Advanc.horm.-depend.prost.Ca treatm.  (S4) DEPOT INJ.11,25 32/21.10/0317, 27/34/0371  thalam.tumours treat appropriat.where necess., incr.risk of ac. por-
       (S4) IMPLANT. A40/21.10/0263  Indications: Palliat.treatm.of advanc.prostat. Ca. when orchiec-  phyr. attacks. in pts with porphyr./fam.hist. thereof & may req.cessat.
       722148-001: 5 mg, 1, R3 213,51  tomy/estrog.admin.not indic./ unaccept. to pt., endometrios.x6
       Dosage: Implant SC into abdom.skin.perform.by medic. practit.  mnths.as sole ther. /surg.adjunct., uter.fibroids x6 mnths.as pre-op.   of treatm., incr.risk of congenit. abnormal., benef.vs.risk in pts.with
                                                                  rec./ ongoing thromboembol.dis./gen.recognis.risk facts. for throm-
       exper.in tumour ther.         ther./symptomat.relief for perimenopaus.pts. not desir.surg., adjuv.
       Recomm.dos: 1 x sngl.dos.once every 12 wks  ther.to surg.in breast Ca.  boembol.events,high.risk for pregn.loss. than follow.natur.concept
                                                                  See also MDR page 502.
       Contraindications: Carcinom.shown to be hormonal. independ.,   875295-002: 11,25 mg, sngl.dos., R5 611,69
       post surgic.castrat., pregn & lactat. as intend.only for use in male pts.  Dosage: Vary inj.sites.  MENOPUR, Ferring &
       Side effects: UTI, anorex., diab.mellit., decr. libido, insomn., par-  Prostate Ca: 11,25 mg 3 mnthly as sngl.IM/SC inj.  Human menopaus.gonadotrophin.(HMG) corresp.to follicle stimu-
       aesthes., ang.pect., dysrhythm., hot flush., dyspn., haemoptys., GI   Endometriosis/uterine fibroids: 11,25 mg 3 mnthly as sngl.   lat.hormone activ.(FSH) 75(600; 1200) IU, luteinis.hormone activ.
       disords., hyperhidros., prurit., dermatit., skin react., abnorm. hair   IM/SC inj.  (LH) 75(600; 1200) IU
       growth, bone pain, musc.weakn., myalg., noctur., dysur., haema-  Breast Ca: 11,25 mg 3 mnthly as sngl. IM/SC inj.  Indications: Female: Infertil.treatm.in WHO group II anovulat.infer-
       tur., pollakiur., micturit. urgency, ED, testicul. disord., gynaecomast.,   Contraindications: Simil.nonapeptide hypersens., undiagn.ab-  til.incl.polycyst.ovar.dis., women unrespons.to clomiphene citr., con-
       testic. pain, inj.site reacts., fatig., oed., pain, asthen., pyrex, chills,   trol. ovar. hyperstimulat.to induc.multipl.follicl. developm.for assist.
       nodule, weight incr., prostat.specif. antig.incr.  norm.vag.bleed., pregn./ poss. pregn., breastfeed., childr.with GnRH/  reproduct.technol.(ART)(eg.in vitro fertilisat./embryo transf.(IVF/ET),
                                     GnRH agon. analog/excipient hypersens.
       Warnings and special precautions: Testost. lev. incr.upon init.  gamete intra-fallopian tfd(GIFT) and intracytoplasm.sperm inj.(ICSI))
       ther.with trans.intensificat.of cert. clin.sympts but regress.over a   Side effects: Asthen., fev., pain, oed., tachycard., bradycard., pal-  Male: Oligosperm., some types of azoosperm., hypogonad., eu-
                                     pitat., ang.pect., arrhythm., CVA’s, TIA’s, MI, CHF, hyper-/hypotens.,
       period of 2 wks., consid.adjuv.admin.of appropr.anti-androg. for   lymphoed., thrombos., vasodilat., GI disturbs.incl.bleed.& pept./   nuchoid.
       init.phase of treatm.to reduc.severity of poss. sequel., monit.pts.  duod.ulc., abdom.distent., dry mouth, thirst, dysphag., gingivit., rect.  (S4/S4) POWD.& SOLV FOR SOL.FOR INJ.,
       with vertebr./cerebr.metastas. &/ urin.tract obstruct.closely esp.  polyps, jaund., abnorm. hepat. funct., diab.mellit., hot flush./sweats,   A39/21.10/0357&A39/34/0412; A44/21.10/0383; 0383
       dur.first wks.of treatm., incr.acid phosphat.levs.dur.init.phase of ther.,   breast disords., decr./incr.libido, anaem., arthropathy, arthralg., bone   708107-001: 75/75 IU, 10x4 ml vials+1 ml amps solv, R2 542,01
       monit.ther.response by meas.testost./acid phosphat. & PSA ser.lev.,   swell., myalg., joint disords., bone pain, musc.weakn., hyperton.,   3000931-001: 600/600 IU, 1x2 ml vial+1x prefill. syr.with solv,
       hypogonad.occurr.dur. long-term ther.may lead to osteoporos.with   R3 202,35
       elev. fract. risk, adjuv.admin.of bisphosphon.may prev. bone dem-  pelv. fibros., ankylos. spondylit., spin.fract., paralysis, tenosynovit.,   3000977-001: 1 200/1 200 IU, 1x2 ml vial+2x prefill. syr.with solv,
                                     nervousn., sleep disords., headache, dizzin., irritabil., neuromyo-
       ineralisat.in pts.at risk, convuls./seiz.& CV hist., monit.diab.mellit.  R4 714,97
       pts.for chang.in gluc. homeostas., assess androgen-sens.of advanc.   pathy, paraesthes., depress., suic.ideat. & attempts., personality   Dosage: Female: Use by physic exper.in infertility problem & man-
                                     disords., periph. neuropathy, syncope, memory impairm., dyspn.,
       prostat. carcinom.at 3 mnths                               agem. Adhere to recomm.dos./ admin. regimen & caref.monit.to
       See also MDR page 686.        pulm.embol./effus., haemopthys., cough, pleural rub, pneum., pulm.   minimis.ovar. enlargem./hyperstimulat. Admin.SC/IM immed. aft.
                                     fibros., asthma, sinus congest., epistax., nasopharyngit., dysphon.,
       LUCRIN, Abbvie [P/S] &        skin/loc.re acts., acne, seborrh., hirsut., ecchymos., alopec., photo-  reconstitut. 600 & 1200 IU presentat.for SC admin only draw.up
       Leuprolide acet.              sens., pigmentat. disord., abnorm.skin odour, dry skin, nail disords.,   exact dos.of reconstit.sol& admin.immed. Indiv.accord.to ovar re-
       Indications: Palliat.treatm.of advanc.prostat.Ca. when orchiec-  abnorm.hair growth, skin carcinoma, prostat. tumor flare, aggrav.of   spons. Admin. alone/in combinat.with gonadotroph.-releas. horm.
                                                                  (GnRH) agonist/antagon.
       tomy/oestrogen admin.not indic./ unaccept.   prostat.Ca., pseudolymph., vag.infect., cervix disord., abnorm. an-
       (S4) INJ. S/21.10/51 5 mg/ml..  drog., viril., noctur., dysur., testicul.disords./ pain, decr.testicul.size,   Women with anovulat.incl.PCOD: Start.treatm. within.init.7
                                                                  days of menstr.cycle. Recomm.init. dos. 75-150 IU dly.x7 days.
       785504-001: 2,8 ml vial+14 syringes, R1 105,13  gynaecomast., erect. dysfunct., UTI’s, micturit.urgency, haematur.,
       Dosage: 1 mg (0,2 ml) as sngl.dly.SC inj.  pollakiuria, bladd.spasms, menstr.disords.incl. breakthrough/ sust.  Adjust accord.to respons. but not more freq.than every 7 days.
       Contraindications: Simil.nonapeptide hypersens., pregn./ poss.  vag.bleed., metrorrhag., dyspareun., uterin.disord., vaginit., menor-  Recomm. dos.increm.37,5 IU/dos.adjustm.& not exceed. 75 IU.
       pregn., breastfeed., undiagn. abnorm.vag.bleed.  rhag. galacthorrh, incontin., penile swell./disords., prostate pain,   Max.dly.dos: 225 IU. If inadeq. respons. aft.4 wks.treatm.abandon.
       Side effects: Init.incr.in ser.androg.lev.of non- orchiectomis. pts.,   urin.obstruct., weight gain/loss, chills, ambylop., dry eye, eye dis-  cycle.& recomm. treatm.at high.start.dos.than that of abandon. cycle.
       incr.in bone pain/exist. haematur., urin.tract.obstruct., low.limb trans.   ords., blurr.vis., vis. disturbs., tinnit., imp.hear., bone density loss/   When optim.respons.obt.admin. sngl. inj.of 5 000-10 000 IU hCG 1
       weakn. & paraesthes., enlarg.abdom., prostat. tumor flare, aggrav.of   change, lymphadenopathy, hypoglycaem., hyperphosphataem.,   day aft.last Menopur inj.& coitus recomm.on day of & day follow.
       prostat.Ca., weight gain/ loss, decr./incr.libido, asthen., chills, fev.,   hypoproteinemia, infect., inflammat., decr./incr.WBC, decr.platelet   hCG admin./perform.IUI.
       gen. pain, headache., infect, inflammat., photosens., swell., CV.effs.,   count, prolong. prothromb.time, high & low density lipoprot. changes,   Controll.ovar.hyperstimulat.for multiple follicul. developm.
       vasc.disords. incl.orthostat. hypotens., CHF, card.arrhythm., MI, phle-  bld.bilirub./urea/creatinine/Ca & uric acid incr., bld.K+decr., preco-  for ART: Protoc.involv. downregulat.with GnRH agon: Start
       bit., pulm. emboli, stroke, syncope/blackouts, tachycard., thrombos.,   cious puberty, pituit. haemorrh., goitre, prostat.specif.antig.incr., ECG   approx.2 wks. aft.start of agon.treatm. Recomm.init.dos. 150-225 IU
                                                                      st
       trans.ischaem.att., varicose veins, diabet. mellit., thyroid enlargem.,   abnorm., cervix neopl., antinucl.antibod.pos., incr RBC sedimentat.  dly.for 1  5 days of treatm. Bas.on clinic. monit.adjust subseq.dos.
       GI disturbs.incl. bleed., pept.ulcerat., rect.polyps, anaem., ecchymos.,   rate, goitre, pituit.apoplex.  accord.to pt. respons. not exceed.150 IU/adjustm. Max.dos. 450 IU
                                                                  dly.& not beyond 20 days.
       lymphoed., bld.dyscras., dehydrat., oed., hyperlipidaem., hyperphos-  Special precautions: Isolat.anaphylax./convuls. has been re-
       phataem., hypoglycaem., hypoproteinaem., potassium.decr, uric acid   port., prostate Ca pts.may exper. tempor. incr.in bone pain/ureter.  Protoc.not involv.downregulat.with GnRH agon: Init.ther.on day
                                                                  2/3 of menstr.cycle using dos. ranges & regim.of protocol.with GnRH
       incr., skin reacts incl.skin/ear Ca., dermatit., hair growth/loss, hard   obstruct.& spin. cord compress. dur.1st wks.of treatm.theref. con-
       nodule in throat, pigmentat., urticar., abnorm./blurr.vis., amblyop., dry   sid. init.ther.with dly.3,75 inj.dur.1st 2 wks.to facilit. poss.withdr.,   agon. downregulat. When suit.number of follicl.reach. approp.size
       eyes, hear.disord., ophthalmolog.disords., taste disords., tinnit., anky-  although ovalutat.is inhib.& menstruat. stops contracept.is not in-  admin.sngl.inj.of up to 10 000 IU hCG to induc.fin.follicul.maturat for
       los.spondylos., bone pain, joint disords./pain, myalg., pelvic.fibros.,   sur.& non-horm. contracept. methods are advis., poss.incr.in clinic.   oocyte retriev. Monit. pt.clos.x2 wks.aft.hCG admin.
       spin. fract., paralys., tenosynovit.like sympts., CNS effs., memory   S&S dur.init.ther.period., chang.in bone min. dens./triglycer.val.,   Men: Recomm.dos.1 vial.IM every other day x90-120 days. If semen
       disords., mood swings, neuromusc. disords., numbn., paresthaes.,   monit.respons.with meas.of testosterone ser.lev., monit.bld.gluc.&/   low.than 1,5 ml add.2 500 IU HCG once/twice wkly.partic.towards
       periph.neuropathy, sleep disords., cough, dyspn., epistax., breath.   HbA1c periodic., monit.pts.with metastat.vertebral lesions &/urin.   end of treatm. Maint: 75-150 IU.every week. Prior to treatm. an as-
                                                                  say of urin.gonadotrophins useful.for discharg. those cases which
       diffic., pleur.rub, worsen.pulm.fibros., pulm. infiltrat, haemoptys.,   tract obstruct., stress import.of contin. ther. & poss.effs to parents.,
       resp.disords., sinus.congest., bladd. spasm, breast pain/tendern.,   monit.S&S suggest. CV dis. develop., consid.benef.of androg.depri-  present above aveg. results.
                                                                  Oligosperm.: Compl.semen exam suffic.
       gynecomast., haematur., incontin., menstr.disords.incl. breakthrough   vat. ther. vs. potent.risks in pts.with congenit.long QT syndr./ electrol.
       & sust.vag.bleed., penile swell. disords., prostate pain, testicul.atro-  abnormalit./CHF/pts.taking class IA or Class III antidysrhythm.meds.,   Azoosperm.: Testicul.biopsy in order to elimin. from treatm.those
       phy/pain, decr. testicul.size, urin.disords./freq./urgency, UTI., mucos.   diagnost.tests of pituit. gonadotrop.& gonad.functs.conduct. dur.   pts.whose seminiferous tubul. contain.only Sertoli’s cells, which
       dryn., PSA incr., bone density loss, anorex., abnorm. hepat.funct.,  treatm.& for 4-8 wks.aft.discontinuat.may be mislead.  do not respond favour.
       Special precautions: Isolat.anaphylax./convuls. report., worsen.of   Contraindications: Pregn.& lactat., tumours in uterus/ovaries/
       S&S of prostat.Ca.dur.ther.init., monit. bld.gluc.&/ HbA1c periodic.,   LUVERIS, (Biopharma Div) Merck &  breast/testes/pituit.gland/ hypothalamus, gynaecolog.bleed.of un-
       pts.with impend. neurolog.comprom.& sev.obstruct. uropathy, monit.  Lutropin alfa. (recombin.human luteinis.hormone)  known orig., pts.present.with polycystic.ovar./capable of ovulat. with
       pts.with urin.tract.obstruct.& metastat. vertebr.les., monit.S&S   Indications: Follicul.developm.stimulat.in women. with sev.LH &   human corionic gonadotroph.(HCG) admin alone, ovar.cysts/enlarg.
       suggest.CV dis. develop., vary inj.site periodic., chang.in bone min.   FSH defic.in assoc.with follicle stimulat.hormone prep.  ovaries not due to polycystic ovar.dis., prim.ovar.fail., sex.organ. mal-
       dens., diagnost.tests of pituit.gonadotrop.& gonad. funct.conduct.  (S4) INJ, 37/21.10/0560  format./uter.fibroid tumours incompat.with pregn.
       dur.treatm.& for up to 3 mths.aft. discontinuat.may be mislead.,   707690-001: 75 IU, 1 vial + solv., R287,57  Side effects: Women: Common: Headache, abdom.pain/-distent.,
       consid.benef.of androg. deprivat.ther.vs.potent.risks in pts.with   Dosage: Only for use by exper.physic. Admin.as course of dly SC   naus., inj.site pain, ovar. hyperstimulat. syndr.(OHSS), pelvic pain.
       congenit. long QT syndr./electrol.abnormalit./CHF/ pts. tak.class IA   inj.simultaneous.with FSH.  Uncommon: Vomit., abdom.discomf., diarrh., fatig., dizzin., ovar.
       or Class III antidysrhythm.meds  Indiv.accord.to pts response assess.by follicle size & oestrog.  cyst, breast complaints, hot flush. Rare: Acne, rash. Unknown:
                                     respons.                     Vis.disords., pyrex., malaise, hypersens.reacts.incl.anaphylact. re-
       LUCRIN DEPOT, Abbvie [P/S] &  Recomm.regim: Commenc.with 75 IU (1 vial) dly. with 75-150 IU FSH.   act., weight incr., musc-skelet.pain, ovar.torsion, prurit., urticar.,
       Leuprolide.                   Adapt.FSH dos.bef adapt. Luveris dos. Adapt FSH dos.pref.aft.7-14 day   thromboembol.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page343.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page339.html">339</a>&nbsp;&nbsp;&nbsp;<a href="page340.html">340</a>&nbsp;&nbsp;&nbsp;<a href="page341.html">341</a>&nbsp;&nbsp;&nbsp;<a href="page342.html">342</a>&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>&nbsp;&nbsp;&nbsp;<a href="page346.html">346</a>&nbsp;&nbsp;&nbsp;<a href="page347.html">347</a>&nbsp;&nbsp;&nbsp;<a href="page348.html">348</a>&nbsp;&nbsp;&nbsp;<a href="page349.html">349</a>
             </td>
             <td width="35%"><a href="page345.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page345.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
